A VISIONaerie™ approach
We discover, develop, and commercialize first-in-class therapies for the treatment of patients with glaucoma, retinal diseases and other diseases of the eye
Press Release
Aerie Pharmaceuticals Completes Enrollment of the Netarsudil... Aerie Pharmaceuticals Announces U.S. Launch of Rocklatan® and... Aerie Pharmaceuticals Matches ASCRS Foundation Fund Raising to Provide...STOCK Quote
NASDAQ: AERI
$23.61USD
Jul 18, 12:12 PM ET
VOLUME
243,477
DAY LOW/HIGH
$23.21/$23.95
52 - WEEK LOW/HIGH
$23.12/$74.75
